Table 2.
HbSS-Townes Mice: Enrichment of Gene-Specific mRNA in Livers and Kidneys of Dimethyl Fumarate-Treated Mice
| Livers | Kidneys | |||
|---|---|---|---|---|
| mRNA | Fold enrichment | p-Value | Fold enrichment | p-Value |
| HO-1 | 2.6 | 0.042 | 1.7 | 0.070 |
| FHC | 3.5 | 0.004 | 1.8 | 0.030 |
| Haptoglobin | 1.9 | 0.045 | 0.14 | 0.180 |
| Hemopexin | 2.4 | 0.022 | 0.42 | 0.138 |
| Nrf2 | 2.3 | 0.018 | 1.5 | 0.014 |
| Ferroportin | 2.7 | 0.008 | 2.0 | 0.065 |
| Glutamate–cysteine ligase catalytic subunit | 2.6 | 0.016 | 1.9 | 0.034 |
| GSTA2 | 2.9 | 0.042 | 20.5 | 0.046 |
| NAD(P)H dehydrogenase [quinone]-1 | 2.9 | 0.026 | 2.8 | 0.021 |
| Glutathione S-transferase Mu 1 | 3.0 | 0.009 | 2.1 | 0.006 |
| Multidrug resistance-associated protein 2 | 2.4 | 0.030 | 3.6 | 0.024 |
Fold enrichment values are calculated as gene-specific mRNA to GAPDH ratios in DMF-treated organs divided by gene-specific mRNA to GAPDH ratios in vehicle-treated organs. HbSS-Townes (n = 3/group) sickle mice with implanted DSFCs were administered DMF (∼30 mg/kg) or vehicle for 7 days.